Impilo-backed Scantox completed the acquisition of the neuropharmacology division of QPS Austria.

Impilo-backed Scantox, a preclinical research company, completed the acquisition of the neuropharmacology division of QPS Austria, a full-service contract research organization. Financial terms were not disclosed. "The acquisition of QPS Neuro is meaningfully changing our lead optimization platform and expands the depth and breadth of our discovery services in the CNS and rare disease area. We see a strong fit with the Scantox organization and are deeply impressed with the dedicated management team, its staff and R&D efforts focused on providing an enhanced level of service and scientific excellence to their clients," Jeanet Løgsted, Scantox CEO.